PDCD1 and cancer: We also found that anti-cancer activity after treatment with anti-PD-1 antibody, CC-01 or CC-01 + anti-PD-1 antibody was boosted by CD4+ T cell deletion, suggesting that CD4+Treg decrease was important factor in immunotherapeutic effect.